AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 11.51 |
Market Cap | 1.40B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.03 |
PE Ratio (ttm) | -374.3 |
Forward PE | n/a |
Analyst | Buy |
Ask | 11.55 |
Volume | 772,681 |
Avg. Volume (20D) | 1,196,093 |
Open | 11.35 |
Previous Close | 11.51 |
Day's Range | 11.07 - 11.41 |
52-Week Range | 7.33 - 23.22 |
Beta | undefined |
About INDV
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorph...
Analyst Forecast
According to 2 analyst ratings, the average rating for INDV stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 42.49% from the latest price.
Next Earnings Release
Analysts project revenue of $260.43M, reflecting a -11.12% YoY shrinking and earnings per share of 0.26, making a -39.53% decrease YoY.